TIDMFUM
RNS Number : 6995A
Futura Medical PLC
26 May 2023
26 May 2023
Futura Medical plc
("Futura" or the "Company")
Notice of AGM and availability of Annual Report
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, today announces its
Annual General Meeting ("AGM") will be held at 10:00am on Thursday
22 June 2023 at the offices of Liberum Capital Limited, Ropemaker
Place, 25 Ropemaker Street, London EC2Y 9LY.
If you wish to attend the meeting in person, please register
your interest, prior to 10:00am on Monday 19 June 2023, at
investor.relations@futuramedical.com.
Shareholders are asked to cast their vote as follows: (1)
casting your proxy vote online by logging on to
www.signalshares.com and following the instructions; or (2) in the
case of CREST members, by utilising the CREST electronic proxy
appointment service; or (3) requesting a hard copy form of proxy
directly from the registrars, Link Group. If you choose to attend
the Annual General Meeting in person instead of appointing the
Chairman of the meeting as proxy, as we strongly recommend, you
will still be able to vote in person at the Annual General
Meeting.
If you are not attending the Annual General Meeting in person,
your proxy vote will need to be logged by 10:00am on Tuesday 20
June 2023 as no online voting will take place in-real time during
the meeting itself.
The Company will operate an audio dial-in facility only to allow
shareholders to listen to the business of the meeting: shareholders
will need to be confirmed as a shareholder or present a letter of
representation before details of how to access this facility are
released to them via email the morning of the meeting. You can
request access by emailing: investor.relations@futuramedical.com
prior to 10:00am on Monday 19 June 2023.
This document should be read in conjunction with the Futura
Medical plc annual report and accounts. If you are in any doubt as
to the action you should take, you are recommended to seek your own
personal financial advice immediately from your stockbroker, bank
manager, solicitor, accountant, or independent advisor, who, if you
are taking advice in the United Kingdom, is authorised pursuant to
the Financial Services and Markets Act 2000.
Shareholders will not get an opportunity to vote or ask
questions or participate in any other way during the call.
Annual Report
Futura's annual report and accounts for the year ended 31
December 2022 (the "Annual Report") is available to shareholders as
an electronic communication pursuant to the Companies Act 2006 and
is now available on the Company's website www.futuramedical.com ,
along with the Notice of AGM.
-ENDS-
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product
differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction ("ED") through a unique
evaporative mode of action. Futura has previously conducted an
initial Phase 3 study using MED3000 in ED, referred to as "FM57"
which enabled Futura to be granted a CE Mark in 2021. A second
confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED
patients and endpoints at 24 weeks, demonstrating that MED3000
presents an effective clinically proven treatment for ED with a
rapid speed of onset and a favourable benefit versus risk profile
ideally suited for an 'Over the Counter' classification.
Eroxon(R) is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile
dysfunction under the brand Eroxon(R) with a key claim of "Helps
you get an erection within 10 minutes". Eroxon(R) is the agreed
brand name in certain regions such as the EU whereas MED3000
continues to be the internal code name used by the Company and also
in reference to countries where regulatory approval or commercial
distribution agreements have not yet been achieved.
www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange. www.futuramedical.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSBXGDUCXDDGXU
(END) Dow Jones Newswires
May 26, 2023 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
